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ABSTRACT 
Pharmaceutical research has developed various new types of innovative forms of drug delivery. Advancement in current drug delivery methods has 
led to the development of numerous new revolutionary technologies that support safe and efficient formulations over existing ones. Novasome 
technology is one of the latest liposome developments that have overcome many of the liposomal drug delivery system-related problems. This 
provides a seven bilayer membrane which is capable of absorbing water-soluble as well as insoluble drugs. The improved efficiency of entrapping 
drugs with good encapsulation features enables better frequency of dosing, which can be accomplished through the high shear system. These find 
their applications in diverse fields such as cosmetics, chemicals, personal care, food, pharmacy, and agrochemicals. Several products have already 
been launched into the market using this technology with an additional launch plan. Due to its depth of penetration, novasomes have been one of 
the most popular derma cosmetics. It is being studied continuously to obtain improved release characteristics. The prospect of drug delivery and 
targeting using novasomes is an important area of research and development. This review pinpoints the various aspect of the novasome and will be 
a milestone for the researchers in the area of drug delivery.  
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INTRODUCTION 
The conception of a drug delivery system (DDS) refers to the process 
of delivering pharmaceutical compounds such as drugs and 
macromolecules at a predefined rate to attain a therapeutic effect in 
animals or humans at a diseased site and, simultaneously, to reduce 
the drug concentration in surrounding tissues. The localized activity 
of the drug promotes the potency or efficacy of the drug and 
decreases the systemic adverse effects on tissues [1]. Over the last 
few decades, a groundbreaking revolution has been undergone in 
the area of the drug delivery system (DDS). The main disadvantage 
of the majority of potential drugs is the failure to attain targeted 
action. Most of the conventional drugs have poor bioavailability and 
cause serious systemic toxicity [2]. To avoid such systemic toxicity, 
novel, sophisticated targeted mechanisms are required for the 
delivery of drugs. In the present scenario of the drug discovery 
system, the vesicular drug delivery systems are promising 
approaches to overcome the limitation of the conventional drug 
delivery system and enable significant drug bioavailability by 
controlled deliverance of therapeutic drugs for an extended period. 
Hence, novasome is an important drug delivery platform for a wide 
range of medicines [3, 4]. They are paucilamellar vesicles shaped by 
many biocompatible phospholipids and single-tailed amphiphiles. 
Therefore, Novasomes can be described as the altered or modified 
form of liposomes which has a diameter of about 0.1-1.0 micron and 
containing 2 to 7 bilayer membranes comprising of unstructured 
space which occupies a huge amorphous nucleus of hydrophobic 
substances (water-insoluble drug substances) and hydrophilic 
substances (water-soluble drug substances) [5]. The diagrammatic 
representation of the novasome is portrayed in fig. 1. Novasome is a 
licensed invention established by the Novavax IGI laboratories. The 
2 to 7 bilayer membrane of novasome aids to integrate both 
hydrophobic as well as hydrophilic drugs. It also aids to overwhelm 
the stability associated problems of liposomes in biological fluids as 
well as their effectiveness in targeting. It's improved encapsulation 
process and efficiency of entrapment improve the dosage frequency. 
Hence, it is used in several fields such as dermatology, food, 
cosmetics, personal care, chemicals, etc. Novasomes may withstand 
some strain and therefore act accordingly. A lot of research is 
underway on this technology as an upheaval in liposome [6, 7].  
Novasome can be said to have enhanced liposomal or niosome 
structure [8]. Liposomes are small sac-like structures that contain 
phospholipids as their monomeric units and they can be found in 
series of sizes with either multilamellar or unilamellar construction, 
and its name refers to its structural building blocks–the 
phospholipids [9, 10]. They are spherical vesicles with a membrane 
made up of cholesterol and phospholipid bilayers, which can 
incorporate a lipid-soluble drug in between two lipid layers and can 
encapsulate an area of the aqueous solution inside a hydrophobic 
membrane core [11]. Niosomes are a multilamellar, non-ionic 
surfactant vesicular structure, similar to liposomes, composed of 
non-ionic surfactants rather than phospholipids, which are 
liposomes components. Because of the presence of non-ionic 
surfactant molecules, it can also entrap both water-soluble and 
water-insoluble drug molecules with greater intrinsic activity. 
Niosomes enhance the clinical efficacy of encapsulated drug 
substances by shielding the drug from extreme biological conditions, 
resulting in impeded clearance of the drug. Niosomes primarily 
comprise two categories of ingredients, i.e. additives and non-ionic 
surfactants. Niosomes have been widely researched in recent years 
for their ability to assist as a transporter for the transmission of 
antigens, hormones, drugs, and other bioactive agents. Niosomes 
have been used to address the issue of toxicity, insolubility, and 
accelerated product degradation [12]. 
The microvesicles of Novasome are immanently stable and are 
designed to be stable at a temperature that varies from liquid 
nitrogen to temperature above the boiling point of water and pH 
ranges from 2 to 13. Sustained-release action is offered by 
novasomes. The Novasome bilayers have no proper array of 
arrangements. Novasomes can sustain any charge, and can therefore 
work accordingly. For instance, if the charge on the microvesicle of 
the novasome is positive, then it can integrate with the hair, mucous 
membrane, or skin of negative charge. In addition to that, they can 
also adhere to hair shafts. Novasome improves treatment efficacy 
and efficiency with virtually no adverse effects. They are natural, 
and they do not cause cytotoxicity of any kind. Due to the wide range 
of pH provided by novasomes, they can be used for a broad range of 
applications. Novasomes can be formulated according to the action 
and level of absorption desired for release [13]. 
Novasome molecules have a hydrophilic head group linked to a 
hydrophobic tail group. These molecules comprise amino acids, 
glycerol-lipids, a long chain of fatty acids, and alcohol derivatives. 
They are normally prepared from a combination of free fatty acid, 
monoester of polyoxyethylene fatty acid, and cholesterol based on 
concentration. The novasome bilayer membranes are formed by a 
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wide range of biocompatible, solitary tailed amphiphiles and 
purposefully selected phospholipids. The tail of fatty acids pointed 
into the inside of the membrane, whereas the polar head groups 
pointed outward. During vesicle production, the hydrophilic 
molecules were admixed with water and placed in aqueous space 
between multiple layers of a lipid bilayer membrane, while the lipid-
soluble molecules were placed within the core of the vesicle. The 
bulk of the novasome vesicles are loaded with the amorphous core, 
which incorporates finely divided insoluble particles such as water-
immiscible compounds, diamonds, and titanium dioxide [14]. The 
diagrammatic representation of the novasome structure is 
portrayed in fig. 1. 
 
 
Fig. 1: Diagrammatic representation showing the structure of novasome [15] 
 
Incompatibility issues in the usage of Novasome technologies can be 
solved by adding different medications within the bilayers. They are 
organic molecules and do not induce any sort of cytotoxicity. 
Novasomes may be designed at the optimal degree of release and 
absorption. Novasomes can be regarded as one of the most 
successful approaches for treating skin disorders. Novasomes are 
the altered forms of niosomes or a variation of liposomes that are 
prepared from the mixture of free fatty acids, cholesterol, and 
monoester of polyoxyethylene fatty acids at a 4/22/74 ratio. Their 
efficiency of encapsulation ranges from 85% for aqueous materials 
to 100% for groups that are present at one surface of the membrane 
point lipid moieties [16]. 
Characteristics of novasome 
The following are the significant characteristics of novasomes;  
• It may be stable over a broad pH range between 2 and 13. 
• It is stable at a temperature between 0 and 100 degrees Celsius, 
i.e. from below the temperature of liquid nitrogen to above the 
temperature of boiling water. 
• They have the benefit of providing more active ingredients in a 
limited volume. 
• They can carry a negative, positive, and neutral charge. 
• It ensures a uniform size distribution and therefore a uniform 
drug or active ingredient content. 
• Up to 80-85 percent of the inner amorphous center can be filled 
with a medicinal drug. 
• It provides a large capacity of the central core due to multi-
bilayer vesicles [17]. 
• It prevents the skin from drying away. 
• Its surface can be charged negatively, positively, or neutrally. 
• It renders targeted and site-specific drug delivery [18]. 
• They have the potential to hold and release a significant amount 
of hydrophilic ingredients. 
• The release rate is predictable. 
• They can adhere to the hair shaft or skin, depending on the 
different circumstances of the surface load of the vesicle as well as 
the thickness of the skin [19]. 
Benefits of novasome over other vesicular drug delivery system 
The following are the significant benefits of novasomes over other 
vesicular drug delivery system;  
• To avoid incompatibility, drugs displaying interactions can be 
integrated in between bilayers of the novasome molecules. 
• Both hydrophobic as well as hydrophilic ingredients can be 
introduced in the same formulation [20].  
• Because of the characteristics of the surface charge, it can be 
made site-specific. 
• It can adhere to the hair shaft or skin, depending on the various 
circumstances. 
• It decreases product irritation and enhances product stability. 
• It is cost-effective in contrast to liposomes and similar 
preparations. 
• Residues are not left on the surface of the skin, and over a 
prolonged period of time, they are rehydrated. 
• They have the ability to deliver a high amount of active 
ingredient because it possesses a loading efficiency of 80 %, thereby 
decreasing drug administration frequency also [21]. 
Mechanism of action of novasome 
The bilayers of the novasome will not give an optimal array layout. It 
comprises channels (vacancies) that serve as a mechanism for 
transporting encapsulated constituents (fig. 2). Encapsulated 
constituents like active compounds (A) in the central core transit 
inside as well as between the individual bilayers (B) through a 
sequence of arbitrary leaps which allows the bilayer vacancies to 
move laterally. This enables the active substituents to be released 
continuously from the lipid bilayers via a watery suspension (C) 
dividing the membrane bilayers. The microvesicle layer can have a 
net charge of negative, positive, or neutral which regulates its 
function. The microvesicles having a positive charge, for example, 
can be combined with skin, mucous membranes, or hair charged 
negatively. Likewise, the arrangement of the vesicles of the 
novasome provides a continuous release system so that the active 
substance is released in a controlled manner [22]. 
Formulation of novasomes 
A powerful shear system that yields greater shear rates is necessary 
for the preparation of novasomes. Micro fluidizers and French 
pressure cells are the systems used to formulate Novasomes. Other 
systems that achieve large shear levels and have the capacity to 
handle heated and semi-viscous lipids can also be utilized. 
Nowadays an innovative technology is used in novasome 
production. It contains a cylindrical blending compartment with a 
tangentially positioned inlet orifice [24]. All the other openings 
result in a storage tank that includes various phases. These comprise 
of the lipophilic and aqueous phase. When the storage tank is 
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attached to the pumps, a turbulent motion is generated inside the 
compartment.  
Normally, the mix used here is a non-phospholipid surface-active, 
charge generating agent, an antioxidant, and a target molecule. The 
same mix is heated initially and then combined. This blend is once 
again mixed with an aqueous phase comprising an aqueous buffer 
and water-soluble collagen. The small vesicles are produced within 
seconds and it is withdrawn from the compartment's axially 
positioned release orifice. An innovative technology for preparing 
the novasomes with N-acyl sarcosinates has now been developed. 
This technique has been employed for the distribution of emollients 
or aromatic oils in a regulated and sustainable manner [25, 26]. 
There are various techniques used in the formulation of novasome 
which are discussed below. 
 
 
Fig. 2: Mechanism of continuous release of active moieties from novasome [23] 
 
Ether injection method 
Here Diethyl ether is mixed with the surface active agent by keeping 
a temperature of 60 °C. The said formulation is exposed to an 
aqueous drug solution with the aid of a 14-gauze needle injection. 
After ether vaporization vesicles having a single layer is obtained.  
Micro fluidization method 
This is the latest approach designed for the production of unilamellar 
vesicles with specified size allocation. This process is commonly 
employed in the formulation of niosomes. This process is concentrated 
on the theory of submerged jet principle, where two fluidized streams 
combine at high speeds, in clearly specified microchannels inside the 
compartment of interaction. Micro fluidization method results in the 
formation of uniform, reproducible and smaller Sized novasomes. 
Handshaking method 
It is also known as the thin-film hydration technique. Here the 
combination of vesicle-generating ingredients such as surfactant and 
cholesterol are incorporated in a round bottom flask of volatile 
organic solvents like diethyl ether, methanol, or chloroform. At room 
temperature (20 °c), the organic solvent is extracted by the means of 
a rotary evaporator that leaves a small film of the solid blend on the 
flask's wall. The extracted film of the surfactant is rehydratable and 
finally, it produces the characteristic multilamellar niosomes [27]. 
Multiple membrane extrusion methods 
The combination of surface-active agent cholesterol and diacetyl 
phosphate in chloroform is transformed into a thin layer by 
evaporation. The thin layer is hydrated using a solution of aqueous 
drugs. The resulting suspension is now extruded via polycarbonate 
membranes. This is an excellent method to manage niosomal size.  
Reverse phase evaporation technique (REV) 
In REV, a combination of ether and chloroform dissolves the 
cholesterol and surface active agent. To this mixture an aqueous phase 
comprising the drug molecules are added and sonicate the following 
phases at 4-5 °C. Upon the introduction of a small quantity of 
phosphate-buffered saline, the transparent gel produced is again 
sonicated. Under low pressure, the organic phase is separated at 40 °C. 
Then the viscous suspension of the niosome developed is mixed with 
saline buffered with phosphate and heated at 60 °C in a water bath 
for 10 min to produce niosome. 
Sonication method 
Here the surfactant-cholesterol combination is initially dispersed in 
the aqueous phase. This mix is then sonicated at 60 °C for 10 min. It 
contributes to multilamellar vesicle (MLV) production. MLVs are 
further ultrasonicated by either a probe or a bath sonicator, this 
results in the production of unilamellar vesicles [28, 29]. 
 
 
Fig. 3: Applications of novasomes [30] 
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Applications of novasomes 
Novasomes are commonly used in the food, cosmetics, personal care, 
chemical, agrochemical, and pharmaceutical industries. The 
applications of the novasome are illustrated in fig. 3. 
Through using non-phospholipid materials, novasomes aid in the 
increase of absorption rate over the topical application of cosmetics 
as well as pharmaceuticals. This benefits to maximize the potency of 
the formulation increases the site distribution of the medication, 
enhances the safety of the lively ingredient in the preparation. 
Novasome vesicles possess the capacity to preserve, carry, and 
distribute a range of nutrients, flavors, and oils such as active 
compounds that can castoff food and beverages. It can intensify 
properties such as consistency, flavoring, aroma, potency, 
protection, firmness, and other needed possessions of essential 
materials such as oils, flavorings, fragrances, etc. This technology can 
be used to produce diverse FDA-regulated products like human 
pharmaceuticals as well as vaccines. Drug delivery mechanisms use 
niosomes via transdermal, parenteral, and ophthalmic pathways are 
well studied. Niosomal transmission through transdermal routes is 
capable of overcoming the sluggish penetration rate of traditional 
transdermal approaches. 
Marketed novasome formulation: Nonphospholipid paucilamellar 
lipid vesicles are marketed in the trade name Novasome (IGI Inc., 
Buena, N. J.). There are many novasome formulations on the market 
(e. g. Novasome A, Novasome D, Novasome Day Cream) containing 
skin-protective agents, oil, moisturizers, and skin-cleaners [31, 32]. 
Some of the novasomal formulations, its ingredients, and its action 
are illustrated below:  
• MPA Hydra-pearls (Novasome Microvesicles)–Humectant [33].  
• Pramoxine HCl Novasome Microvesicles which is incorporated 
in MPA Dermal-Soothe Spray is intended for cell repair, antipruritic, 
humectant. 
• 2.5% Benzoyl Peroxide; Novasome Microvesicles embodied as 
MPA Benzoyl-Plus are beneficial for keratolysis, bacterial infection, 
humectant, follicular flushing [34]. 
• Nova Pearls that are slow-release power moisturizers are 
geared towards deodorizer for maintenance of pets skin [35].  
• Acne Worx that contains 2% salicylic acid is helpful to reduce 
acne blemishes and to avoid fresh pimples beforehand.  
• MPA Miconazole Shampoo which consists of 1% Miconazole 
Nitrate, a Novasome Microvesicles are aimed at fungal infection, 
Antibacterial, Keratolytic, Keratoplastic [36, 37].  
Recent advances in novasome technology 
Recent developments in innovative skills allowed novasome to be 
tested for encapsulation, flavor, and as adjuvants in vaccine research, 
and in the sophisticated derma cosmetic technology that extends the 
dermatology boundaries and is clearly depicted in fig. 4. Not only can 
novasome vesicles quickly pierce the innermost layers of the skin, but 
also penetrate as pre-programmed into the desired cell [38]. 
 
 
Fig. 4: Novasome penetration to the deepest layers of skin [39] 
 
Novasome dermatological preparations developed at Cornell 
University have been tested in 2 usual clinical contexts. The initial 
research investigated the effectiveness of novasomes for cold, dog 
skin during winter based on and non-encapsulated emollients, 
where twenty dogs were administered two types of medication. 
Those outcomes revealed in 80 percent of the Dogs, the Emollient 
related Novasome was the top agent. Those research had shown that 
Novasome can act as potent Humectants. The later research 
analyzed shampoos based on Novasome and Non-Novasome 
containing benzoyl peroxide. Test effects revealed that novasome-
built shampoos diminished scaling by 70 percent while Non-
Novasome-built diminished scaling by just 20 percent [40].  
Novasome-related extended-release veterinary medicines are also 
licensed for extended skin hydration and antipyretic agent transfer 
to pets. Continued discharge processing uses innovative 
microvesicles to condense moisture to achieve hydrating results 
when applying the skin, shampoo, and sprays. These non-ionic 
vesicles of glyceryl dilaurate using polyoxyethylene-10-stearyl ether 
as well as cholesterol are identified to spread larger quantities of 
cyclosporine in as well as over the mouse skin than vesicles based 
on ceramide or phosphatidylcholine [41, 42]. As a lotion or cream, it 
has been found to be beneficial for topical delivery into the damaged 
area. Studies displayed novasome skill has the better quality for the 
localized transport of H2 antagonists for the treatment of parodontal 
ailment because of augmented local absorption of H2 antagonists 
and increased action of drug [43]. This will also be utilized in 
treating inflammatory skin and other conditions.  
This knowledge is widely utilized in vaccine grounding [44, 45]. A 
smallpox vaccine centered on Novasome had been established. The 
new novasome-centered vaccine is also in advancement. For the 
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control of the Avian Rheovirus and New Castle Disease virus species, 
novasome-centric vaccines were cast-off. Novasome microvesicles 
deactivate viruses like coronaviruses, orthomyxoviruses, 
retroviruses, and paramyxoviruses by mixing them immediately 
after union with the enclosed virus and the nucleic acid virus. The 
novasomes can be transmitted as an adjuvant in vaccines. 
Novasomes were recognized to be a powerful adjuvant for human 
vaccines (aluminum phosphate) when Gupta et al. [46] tested 
Novasome made from oleic acid, cholesterol, and dioxyethylene cetyl 
ether with tetanus toxoid and diphtheria toxoid. Chambers et al. [47] 
established that they were secured from fatal tuberculosis by a 
single dose of formalin impaired BCG assorted with Novasome when 
directed to guinea pigs as a single subcutaneous injection. Another 
method patented included the preparation of the surfactant-
containing novasome (NONOXYNOL-9) which are latex compliant 
and for inactivation of enveloped viruses and spermatozoa in touch. 
Usage of Wright [48] oral vaccines to prevent gram-negative 
bacterial infections by novasome-WFI diluents (paucilamellar, non-
phospholipid encapsulated cherry oil). Novasome lipid vesicles are 
combined with WFI in the preparation for an oral vaccine in a ratio 
of Novasome: WFI 1:32(v/v) to conserve 99.2 percent of water. 
Pushko et al. have utilized the Novasome microvesicles as a 
candidate for avian influenza as an adjuvant of the influenza virus, 
including particulates [49]. Holick et. al successfully encapsulated 
the Parathyroid hormone analog PTH (1-34) in Novasome cream, 
improved the absorption of this peptide product into the human 
skin. The erythema and scaling of the psoriatic lesions, with the 
usage of PTH (1-34) disclosed clear expansion. There was major 
progress in erythema and scaling of the psoriatic lesions treated 
with PTH (1-34) [50]. This was the first proof that a peptide drug 
was successfully formulated to treat skin diseases [51]. Minoxidil's 
topical formulation has been improved by creating it further 
hydrophilic by using novasome microvesicle as well as organic acid, 
or a base like lactic acid. Fuels combined with patented lipid vesicles, 
dispersion-assistant molecules have been used to transport water as 
well as water-soluble fuel additives in fuels and have improved 
performance characteristics compared to traditional fuels [52]. 
Novasomes indicate higher tolerance to acidity, alkalinity, and 
temperature. Often, goods could be combined effortlessly by using 
those tools. Some of the currently available marketed products of 
novasome are listed below in table 1. 
 
Table 1: Currently available marketed products of novasome 
S. No. Marketed formulation Manufacturing company Applications References 
1. Novasomes Neutrogena, Estee Lauder, Pierre Fab It is used in cosmetics. [53] 
2. Moisturizing cream and gel in its popular 
Water Bank products line 
Amore Pacific It is used for body skin. [53] 
3. Acne-worx Dermworx It is used in adult acne product. [54] 
4. Retinoid products Johnson and Johnson It is mainly used for skin care. [55] 
5. Icy Hot cream, patches and lotions Chattem Pharmaceuticals It is used as a line of over the 
counter pain therapy. 
[56] 
6. Skincare products Dermatology Associates of Georgia It is used for care. [57] 
7. MIAJ anti-wrinkle cosmetics IGI It is used in cosmetics. [58] 
8. Pharmaceuticals, grooming and vaccines Vetoquinol USA It is used for animal care. [58] 
9. Relieva cream, shampoo and lotions Apollo Pharmaceuticals It is mainly used for the 




Various studies have concluded that novel technology has shown 
more product strength, the half-life rises from weeks to years at 
times, prevents oxidation and emulsification, and also license the 
shielding of antagonistic components in the formulation till usage. 
Besides, novasomes allow the regulation of the release of lively 
elements overpressure, heat, and/or time. Time-release is 
exclusively advantageous as it has been revealed to be highly 
effective and slightly a few harmful effects than medicines which at 
one time dump a full dose on the skin. Trapping efficacy has been 
shown. The marginal cost of fabricating goods using novasomes is 
negligible. Any proprietary evidence shows its widespread use in 
pharmaceuticals, milk, agrochemicals, and so on. Through the use of 
advanced technology, numerous dermatological therapies have 
exposed new progress in their efficiency. Continuous progress is 
being made in the innovative technology market. A variety of 
novasome-based products are in development for market access.  
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